%AHainline, Kelly [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AHainline, Kelly%AShores, Lucas [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AShores, Lucas%AVotaw, Nicole [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AVotaw, Nicole%ABernstein, Zachary [Biomedical Engineering Department, Duke University, Durham, NC 27708]%ABernstein, Zachary%AKelly, Sean%AKelly, Sean [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AFries, Chelsea%AFries, Chelsea [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AMadhira, Marisha%AMadhira, Marisha [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AGilroy, Caslin [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AGilroy, Caslin%AChilkoti, Ashutosh [Biomedical Engineering Department, Duke University, Durham, NC 27708]%AChilkoti, Ashutosh%ACollier, Joel [Biomedical Engineering Department, Duke University, Durham, NC 27708]%ACollier, Joel%BJournal Name: Proceedings of the National Academy of Sciences; Journal Volume: 118; Journal Issue: 15; Related Information: CHORUS Timestamp: 2023-11-01 13:41:52 %D2021%IProceedings of the National Academy of Sciences %JJournal Name: Proceedings of the National Academy of Sciences; Journal Volume: 118; Journal Issue: 15; Related Information: CHORUS Timestamp: 2023-11-01 13:41:52 %K %MOSTI ID: 10220461 %PMedium: X %TModular complement assemblies for mitigating inflammatory conditions %XSignificance

Current treatments for chronic inflammatory conditions rely on biologic drugs, commonly monoclonal antibodies that interfere with inflammatory signaling pathways. These drugs have made enormous contributions to the treatment of inflammatory diseases but still possess considerable drawbacks, including high cost that limits access in low-resource settings, the requirement for regularly repeated injections, and uneven efficacy. As an alternative to such biologics, active immunotherapies, in which an individual is induced to generate their own therapeutic antibodies, offer considerable potential advantages. Here, we report chemically defined nanomaterials inducing therapeutic responses in two models of inflammation in mice. The materials were produced by coassembling defined T cell epitopes, B cell epitopes, and an engineered fragment of complement protein C3dg into defined nanomaterials.

%0Journal Article